Animalcare Group plc Stock

Equities

ANCR

GB0032350695

Pharmaceuticals

Delayed London S.E. 06:39:03 2024-04-29 EDT 5-day change 1st Jan Change
224 GBX +3.23% Intraday chart for Animalcare Group plc +3.23% +31.76%

Financials

Sales 2023 74.35M 93.17M 127M Sales 2024 * 74.85M 93.79M 128M Capitalization 130M 163M 223M
Net income 2023 1M 1.25M 1.71M Net income 2024 * 28M 35.09M 47.9M EV / Sales 2023 1.37 x
Net Debt 2023 * 1.2M 1.5M 2.05M Net cash position 2024 * 27.1M 33.96M 46.36M EV / Sales 2024 * 1.38 x
P/E ratio 2023 *
-
P/E ratio 2024 *
-
Employees 220
Yield 2023 *
2.03%
Yield 2024 *
2.3%
Free-Float 64.4%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.23%
1 week+3.23%
Current month+6.67%
1 month+5.66%
3 months+26.20%
6 months+29.86%
Current year+31.76%
More quotes
1 week
214.00
Extreme 214
225.00
1 month
204.00
Extreme 204
225.00
Current year
165.00
Extreme 165
230.00
1 year
160.00
Extreme 160
230.00
3 years
145.00
Extreme 145
430.00
5 years
132.06
Extreme 132.055
430.00
10 years
112.00
Extreme 112
430.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 18-08-02
Director of Finance/CFO 48 12-05-31
Human Resources Officer - 10-11-30
Members of the board TitleAgeSince
Director/Board Member 59 17-07-12
Director/Board Member 64 22-05-02
Director/Board Member 63 17-07-12
More insiders
Date Price Change Volume
24-04-29 224 +3.23% 25 271
24-04-26 217 0.00% 43,842
24-04-25 217 0.00% 10,188
24-04-24 217 0.00% 13,944
24-04-23 217 0.00% 69,209

Delayed Quote London S.E., April 29, 2024 at 06:39 am

More quotes
Animalcare Group plc is a United Kingdom-based international veterinary sales and marketing company. The Company is focused on bringing products to market through its own development pipeline, partnerships and through acquisitions. The Company develops and commercializes prescription and over-the-counter pharmaceutical products that improve animal health and wellbeing. These are developed in-house, acquired from other companies or in-licensed from its partners. The Company manages an international supply chain, including specialist veterinary wholesalers and distributors. It partners with companies to commercialize products across Europe. The Company operates in three categories within the veterinary market: companion animals, equine and other, and production animals. Its product pipeline is Daxocox, which is a differentiated COX-2 inhibitor for the treatment of chronic pain in dogs. The Company operates in seven countries and exports to about 40 countries in Europe and worldwide.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.17 GBP
Average target price
2.935 GBP
Spread / Average Target
+35.25%
Consensus

Annual profits - Rate of surprise